Your browser doesn't support javascript.
loading
Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist.
Kawai, Takahiro; Sun, Bingfa; Yoshino, Hitoshi; Feng, Dan; Suzuki, Yoshiyuki; Fukazawa, Masanori; Nagao, Shunsuke; Wainscott, David B; Showalter, Aaron D; Droz, Brian A; Kobilka, Tong Sun; Coghlan, Matthew P; Willard, Francis S; Kawabe, Yoshiki; Kobilka, Brian K; Sloop, Kyle W.
Afiliación
  • Kawai T; Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka 412-8513, Japan.
  • Sun B; ConfometRx, Santa Clara, CA 95054.
  • Yoshino H; Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka 412-8513, Japan.
  • Feng D; ConfometRx, Santa Clara, CA 95054.
  • Suzuki Y; Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka 412-8513, Japan; suzukiysy@chugai-pharm.co.jp kobilka@stanford.edu sloop_kyle_w@lilly.com.
  • Fukazawa M; Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka 412-8513, Japan.
  • Nagao S; Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka 412-8513, Japan.
  • Wainscott DB; Quantitative Biology, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285.
  • Showalter AD; Diabetes and Complications, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285.
  • Droz BA; Diabetes and Complications, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285.
  • Kobilka TS; ConfometRx, Santa Clara, CA 95054.
  • Coghlan MP; Diabetes and Complications, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285.
  • Willard FS; Quantitative Biology, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285.
  • Kawabe Y; Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka 412-8513, Japan.
  • Kobilka BK; ConfometRx, Santa Clara, CA 95054; suzukiysy@chugai-pharm.co.jp kobilka@stanford.edu sloop_kyle_w@lilly.com.
  • Sloop KW; Diabetes and Complications, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285 suzukiysy@chugai-pharm.co.jp kobilka@stanford.edu sloop_kyle_w@lilly.com.
Proc Natl Acad Sci U S A ; 117(47): 29959-29967, 2020 11 24.
Article en En | MEDLINE | ID: mdl-33177239
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Receptor del Péptido 1 Similar al Glucagón / Dominios Proteicos / Hipoglucemiantes Límite: Animals / Humans / Male Idioma: En Revista: Proc Natl Acad Sci U S A Año: 2020 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Receptor del Péptido 1 Similar al Glucagón / Dominios Proteicos / Hipoglucemiantes Límite: Animals / Humans / Male Idioma: En Revista: Proc Natl Acad Sci U S A Año: 2020 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Estados Unidos